Medico Remedies Share Price Today | Stock Price & Medico Remedies Share Screener
As of October 5, 2026, the live Medico Remedies share price (NSE: MEDICO) is ₹21.68 on NSE and ₹21.83 on BSE, down 0.82% from the previous close, with shares trading between ₹21.50 and ₹22.59 in today's trading session, and a 52-week range of ₹21.53–₹54.24. Check MEDICO 52-week high low for the annual price range and momentum. Use the Medico Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Medico Remedies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹244 and net income of ₹14, with EBITDA of ₹24, an operating margin of 8.0% and a profit margin of 5.7%.
Medico Remedies Share Price Chart
Track the current stock price of Medico Remedies with an interactive chart. Analyse MEDICO share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Medico Remedies stock quote in one place.
The quote of ₹21.68 sits between the 52-week low of ₹21.53 and the 52-week high of ₹54.24, and the latest session moved -0.82% from the previous close.
Medico Remedies Company Profile - Fundamental Screener
Screen Medico Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MEDICO shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE630Y01024.
Company Details
Classification
Identifiers and Leadership
Medico Remedies Balance Sheet Screener
Screen MEDICO balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹153, up from ₹120 in 2025.
Latest statistics put total assets at ₹153 and shareholder funds at ₹76, with a leverage ratio of 0.24.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 153 | 120 | 96 | 87 | 77 | 76 | 75 | 76 | 59 | 48 |
| Current Assets | 129 | 97 | 74 | 65 | 58 | 59 | 57 | 59 | 46 | 38 |
| Fixed Assets | 20 | 21 | 22 | 22 | 18 | 15 | 13 | 12 | 7 | 7 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 1 | 2 | 3 | 5 | 5 | 3 | 3 | 11 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 76 | 63 | 52 | 44 | 37 | 33 | 30 | 28 | 27 | 16 |
| Share Capital | 17 | 17 | 17 | 17 | 17 | 4 | 4 | 4 | 4 | 3 |
| Reserves & Surplus | 59 | 46 | 36 | 27 | 20 | 28 | 26 | 24 | 23 | 13 |
Medico Remedies Income Statement Screener - Profit & Revenue Analysis
Screen Medico Remedies income statement and profit fundamentals. Analyze MEDICO quarterly results. Medico Remedies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹244 and net profit was ₹14, equal to earnings per unit of ₹1.70, at an operating margin of 8%.
In that period expenses were ₹220, interest cost ₹2 and tax ₹5. The next period listed, 2026-March, shows revenue of ₹212 and net profit of ₹13.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 244 | 212 | 154 | 147 | 144 | 123 | 123 | 91 | 100 | 62 | 55 | 67 | 51 |
| Expenses | 220 | 189 | 136 | 132 | 131 | 114 | 117 | 86 | 95 | 58 | 50 | 63 | 48 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 24 | 23 | 18 | 15 | 14 | 9 | 6 | 5 | 5 | 4 | 4 | 4 | 3 |
| Operating Profit % | 8.00% | 8.00% | 10.00% | 9.00% | 7.00% | 6.00% | 4.00% | 3.00% | 3.00% | 6.00% | 7.00% | 5.00% | 6.00% |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Interest | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 19 | 18 | 14 | 11 | 10 | 7 | 4 | 2 | 2 | 2 | 2 | 2 | 1 |
| Tax | 5 | 5 | 3 | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 1 | 0 |
| Net Profit | 14 | 13 | 10 | 8 | 7 | 5 | 3 | 2 | 2 | 1 | 2 | 1 | 1 |
| EPS | 1.70 | 1.58 | 1.22 | 1.00 | 0.87 | 0.58 | 1.56 | 3.93 | 3.78 | 3.65 | 5.09 | 3.53 | 5.91 |
Medico Remedies Cash Flow Screener - Liquidity Fundamentals
Screen MEDICO cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹6, and net cash flow was an inflow of ₹1.
Over the same period, investing activities used ₹5 and financing activities used ₹1.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 6 | 5 | 2 | 8 | 6 | -11 | 1 | 5 | 5 | -3 |
| Investing Activities | -5 | -4 | -3 | -7 | -2 | -17 | -3 | -4 | -5 | -3 |
Financing and Net Cash | ||||||||||
| Financing Activities | -1 | -1 | -1 | -2 | -6 | 18 | 3 | -1 | -1 | 6 |
| Net Cash Flow | 1 | 1 | -1 | 0 | -2 | -10 | 1 | 0 | -1 | 0 |
Medico Remedies Shareholding Pattern Screener
See Medico Remedies shareholding pattern with promoter, FII, and DII holdings. Check Medico Remedies promoter holding and ownership changes for MEDICO on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 61.38%, foreign institutions 0.03%, domestic institutions 0.00% and the public 23.56%, spread across 16,189 shareholders.
The shareholder count was 16,189 in 2026-Mar, compared with 15,863 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 61.38% | 61.38% | 63.79% | 62.59% | 61.38% | 61.38% | 73.34% | 73.34% |
Institutional Investors | ||||||||
| FII Holding | 0.03% | 0.08% | 0.12% | 0.07% | 0.30% | 0.49% | 0.29% | 0.23% |
| DII Holding | 0.00% | 0.00% | 0.01% | 0.01% | 0.01% | 0.00% | 0.74% | 0.97% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.56% | 23.68% | 22.13% | 22.79% | 23.11% | 22.72% | 14.39% | 17.49% |
| Other Holding | 15.03% | 14.86% | 13.94% | 14.53% | 15.19% | 15.41% | 11.24% | 7.98% |
| Shareholder Count | 16,189 | 15,863 | 15,424 | 16,474 | 18,503 | 16,562 | 10,685 | 12,902 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Medico Remedies. Medico Remedies dividend yield can be compared with peers and other stocks in the market.
Medico Remedies Stock Index Membership - Nifty & Sensex
See which indices include Medico Remedies stock. Check MEDICO index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Medico Remedies Market Events Screener - Corporate Actions
Get Medico Remedies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Medico Remedies stock events that may affect MEDICO share price, along with derivatives, futures and options activity and sector gainers.
13 corporate actions are listed, the most recent entry being Annual General Meeting dated September 22, 2026, with a record date of September 22, 2026.
It is followed by Quarterly Result Announcement dated August 13, 2026 and Quarterly Result Announcement dated May 21, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-22 | 2026-09-22 | Annual General Meeting | NA | -19.59% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | 1.39% |
| 2026-05-21 | 2026-05-21 | Quarterly Result Announcement | NA | 6.05% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 1.28% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 7.58% |
| 2025-09-08 | 2025-09-08 | Annual General Meeting | NA | -0.25% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -4.01% |
| 2025-05-08 | 2025-05-08 | Quarterly Result Announcement | NA | -5.84% |
| 2025-02-05 | 2025-02-05 | Quarterly Result Announcement | NA | 1.85% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 4.05% |
| 2024-09-05 | 2024-09-05 | Annual General Meeting | NA | 20.82% |
| 2023-03-16 | 2023-03-16 | Split | 2:10 | 16.61% |
| 2021-11-16 | 2021-11-17 | Bonus | 3:1 | -7.80% |
Medico Remedies Competitors Screener - Peer Stocks Comparison
Screen MEDICO competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 447,476 | 36.44 | 61,674 | 12.69% | 11,565 | 47.42 |
| Divis Laboratories | 250,363 | 86.51 | 11,067 | 13.95% | 2,568 | 58.71 |
| Torrent Pharmaceuticals | 186,152 | 85.91 | 13,886 | 20.34% | 2,138 | 48.14 |
| Zydus Life Science | 120,798 | 26.32 | 27,658 | 17.64% | 5,026 | 61.81 |
| Cipla | 111,426 | 33.44 | 29,045 | 2.24% | 3,870 | 44.03 |
| Laurus Labs | 106,838 | 99.70 | 6,868 | 22.01% | 890 | 58.00 |
| Mankind Pharma | 105,107 | 48.73 | 14,636 | 14.85% | 1,938 | 64.24 |
| Dr Reddys Laboratories | 104,492 | 32.05 | 35,059 | 3.90% | 4,158 | 69.59 |
| Aurobindo Pharma | 97,682 | 26.36 | 34,145 | 5.56% | 3,503 | 54.69 |
| Lupin | 93,829 | 16.99 | 29,039 | 26.75% | 5,356 | 34.02 |
Medico Remedies Company Announcements - News & Reports Screener
Screen MEDICO latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated .
The next most recent announcements are dated September 29, 2026 and September 28, 2026.
| Date | Update | Actions |
|---|---|---|
| Closure of Trading Window | - | |
| 2026-09-29 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-28 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-29 | Reg. 34 (1) Annual Report. | - |
| 2026-08-29 | Intimation Of Book Closure Date Pursuant To Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | - |
| 2026-08-29 | Submission Of Annual Report For The Financial Year 2025-26 Along With The Notice Of The 32Nd Annual General Meeting | - |
| 2026-08-17 | Clarification On Price Movement | - |
| 2026-08-13 | Financial Results For The Quarter Ended On 30Th June 2026 | - |
| 2026-08-10 | Board Meeting Intimation for Intimation Of Board Meeting. | - |
| 2026-08-05 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | - |
| 2026-08-03 | Clarification sought from Medico Remedies Ltd | - |
| 2026-06-30 | Closure of Trading Window | - |
| 2026-06-29 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-06-03 | Intimation Of Action Taken Or Order Passed By Regulatory Statutory Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-21 | Audited Standalone Financial Results Of The Company For The Quarter Ended 31St March 2026 And Audited Financial Statements For The Year Ended On 31St March 2026 Along With The AuditorS Report Thereon | - |
| 2026-05-21 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-05-21 | Board Meeting Outcome for Outcome Of Board Meeting Held Today | - |
| 2026-05-15 | Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday 21St May 2026 | - |
| 2026-04-16 | Intimation Of Action Taken Or Order Passed By Regulatory Statutory Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations) | - |
| 2026-02-24 | Intimation Of Action Taken Or Order Passed By Regulatory Statutory Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations) | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹21.68, within a 52-week range of ₹21.53 to ₹54.24. The P/E ratio is 13.43 and the P/B ratio is 2.45, with earnings per unit of ₹1.58. Market capitalisation stands at ₹181.24 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.